Madonna
Laufzeit: 01.01.2009 - 31.12.2011
Kurzfassung
"Randomized, double blind Phase II study of Docetaxel + Sorafenib (Nexavar)
versus Docetaxel + Placebo in First-Line treatment of patients with HER
negative, metastatic breast cancer"
Laufzeit: 01.01.2009 - 31.12.2011
"Randomized, double blind Phase II study of Docetaxel + Sorafenib (Nexavar)
versus Docetaxel + Placebo in First-Line treatment of patients with HER
negative, metastatic breast cancer"
